

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4622166

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
LENNART LINDFORS	12/09/2016
TOMAS KJELLMAN	12/12/2016
RECEIVING PARTY DATA	
Name:	ASTRAZENECA AB
Street Address:	SE-151 85
City:	SODERTALJE
State/Country:	SWEDEN
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15589181
CORRESPONDENCE DATA	
Fax Number:	(301)398-9306
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	301-398-0000
Email:	patents@astrazeneca.com
Correspondent Name:	ASTRAZENECA MEDIMMUNE
Address Line 1:	ONE MEDIMMUNE WAY
Address Line 4:	GAITHERSBURG, MARYLAND 20878
ATTORNEY DOCKET NUMBER:	200410-US-NP
NAME OF SUBMITTER:	KIM NOROOZI
SIGNATURE:	/Kim Noroozi/
DATE SIGNED:	10/02/2017
Total Attachments: 4	
source=2016_12_09_executed_Lindfors_etal_P2#page1.tif	
source=2016_12_09_executed_Lindfors_etal_P2#page2.tif	
source=2016_12_09_executed_Lindfors_etal_P2#page3.tif	
source=2016_12_09_executed_Lindfors_etal_P2#page4.tif	

ASSIGNMENT OF INVENTION MADE DURING EMPLOYMENT

§1

The undersigned, Lennart LINDFORS (SE citizen) of AstraZeneca, SE-431 83 Mölndal, Sweden (Inventor(s) Address) as of the 9th May 2016 (Priority filing date) (the "Effective Date") hereby confirms that by virtue of their employment have assigned, and in so far as there may be any outstanding rights that have not been assigned do hereby assign, to AstraZeneca AB with registered office address at SE-151 85 Södertälje, Sweden ("AstraZeneca") an invention made during employment, which invention, in accordance with the rules laid down in the collective bargaining agreement between SN (the Swedish Employers' Confederation) and PTK (the Swedish Federation of Salaried Employees in Industry and Services) dated 2 July, 2015, has been brought to the attention of the employer and has been categorized as a Class A Invention.

§2

This assignment comprises the Inventor(s) entire right, title and interest to said invention made by them and to any and all patents that may be granted thereon, including, but not limited to, the patent applications specified in US Provisional Application No. 62/359429 filed on the 7th day of July 2016 (the "Patent Application").

§3

The assignment as stated in §2, above, includes, but is not restricted to, the right without limitation to apply for, to be granted and to assign patents and other means of protection of industrial property that may be granted on said invention (including, but not limited to, design registration and inventor's certificates rights), the right to any divisions, continuations, continuations-in-part, re-issues, re-examinations, or extensions of the Patent Application(s), the right to file patent applications directly in the name of AstraZeneca or an affiliated company of AstraZeneca, and the right to file a patent application anywhere in the world claiming convention priority.

§4

The Inventor(s) hereby confirm(s) that calculation of the remuneration for the invention assigned to AstraZeneca shall be subject to the rules stated in the Policy on Inventor Remunerations, dated 11 November, 2015, as to providing incentives for inventors among employees of the AstraZeneca group of companies.


§5

The AstraZeneca group of companies are entitled at any time to waive their rights to the invention in favour of the Inventor(s), in which case any remuneration already paid out is not required to be refunded.


Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Signed at:

Date: Dec 9, 2016


Name: Lennart LINDFORS

Witnessed by:



Name: Anita Håkansson
Pepparedsleden 1
431 83 Mölndal
Sweden

The above assignment agreement is accepted:

Signed at:

Date: 14th February 2017

Signed for and on behalf of
ASTRAZENECA AB (PUBL)


Sally CURRAN
Authorised Signatory

Witnessed by: B. Ince

Name: B. INCE

ASSIGNMENT OF INVENTION MADE DURING EMPLOYMENT

§1

The undersigned, Tomas KJELLMAN (SE citizen) c/o AstraZeneca Intellectual Property, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom as of the 9th May 2016 (Priority filing date) (the "Effective Date") hereby confirms that by virtue of their employment have assigned, and in so far as there may be any outstanding rights that have not been assigned do hereby assign, to AstraZeneca AB with registered office address at SE-151 85 Södertälje, Sweden ("AstraZeneca") an invention made during employment, which invention, in accordance with the rules laid down in the collective bargaining agreement between SN (the Swedish Employers' Confederation) and PTK (the Swedish Federation of Salaried Employees in Industry and Services) dated 2 July, 2015, has been brought to the attention of the employer and has been categorized as a Class A invention.

§2

This assignment comprises the Inventor(s) entire right, title and interest to said invention made by them and to any and all patents that may be granted thereon, including, but not limited to, the patent applications specified in US Provisional Application No. 62/359429 filed on the 7th day of July 2016 (the "Patent Application").

§3

The assignment as stated in §2, above, includes, but is not restricted to, the right without limitation to apply for, to be granted and to assign patents and other means of protection of industrial property that may be granted on said invention (including, but not limited to, design registration and inventor's certificates rights), the right to any divisions, continuations, continuations-in-part, re-issues, re-examinations, or extensions of the Patent Application(s), the right to file patent applications directly in the name of AstraZeneca or an affiliated company of AstraZeneca, and the right to file a patent application anywhere in the world claiming convention priority.

§4

The Inventor(s) hereby confirm(s) that calculation of the remuneration for the invention assigned to AstraZeneca shall be subject to the rules stated in the Policy on Inventor Remunerations, dated 11 November, 2015, as to providing incentives for inventors among employees of the AstraZeneca group of companies.

§5

The AstraZeneca group of companies are entitled at any time to waive their rights to the invention in favour of the Inventor(s), in which case any remuneration already paid out is not required to be refunded.


Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Signed at:

Date: 2016-12-12


Name: Tomas KJELLMAN

Witnessed by:



Name:

The above assignment agreement is accepted:

Signed at:

Date: 14th February 2017

Signed for and on behalf of
ASTRAZENECA AB (PUBL)


Sally CURRAN
Authorised Signatory

Witnessed by: 

Name: B. NCE